- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01727778
Safety and Preliminary Efficacy Study of the Antibody PAT-SM6 in Patients With Relapsed or Refractory Multiple Myeloma
Open-label, Single-centre, Phase I, Multi-dose Escalating Study to Investigate the Safety and Preliminary Efficacy of an i.v. Infusion of the Anti-GRP78 Monoclonal IgM Antibody PAT-SM6 in Patients With Relapsed or Refractory Multiple Myeloma
Primary
- To evaluate the safety and tolerability of escalating doses of an intravenous (i.v.) infusion of PAT-SM6 in subjects with relapsed or refractory multiple myeloma.
Secondary
- To evaluate the efficacy and pharmacodynamics by analysis of serum and urine M protein, serum free light chains (FLC) κFLC and λFLC, total immunoglobulins, β2-microglobulin, C-reactive protein (CRP), exploratory biomarkers and anti-PAT-SM6 antibodies.
- To evaluate the duration of response and the progression free survival.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Open-label, single-centre, dose escalation phase I study designed to investigate the safety and tolerability of intravenous (i.v.) infusions of PAT-SM6 administered over 90 minutes.
A screening examination will be performed within 14 days prior to dosing. Eligible subjects will receive 4 doses of PAT-SM6 (cycle 1: Day 1 and Day 3, cycle 2: Day 8 and Day 10). Subjects will be hospitalised for at least 48 hours after each dose administration (i.e. from Day 1 to Day 5 in cycle 1 and from Day 8 to Day 12 in cycle 2). During hospitalisation subjects will be under constant surveillance. Subjects will return for ambulatory visits on Days 15, 22, 29 and 36 for safety, pharmacokinetic (PK) and pharmacodynamic (PD) assessments.
Serological staging will be performed at baseline, on Day 29 (+/- 2 days) and Day 36 (+/-2 days). Response will be assigned by the International Myeloma Working Group (IMWG) uniform response criteria for multiple myeloma. Complete response (CR) will be confirmed by bone marrow aspiration; CT scans or other radiograph are only intended when clinical symptoms are suspicious for progressing disease or otherwise clinically indicated.
If a subject shows an at least partial response (PR) on Day 29 or Day 36 (4 doses) the sponsor discusses with the Data Safety Monitoring Board (DSMB) to give an additional 2 doses (therefore the maximal number of doses for each subject is 6 doses) and a further staging will be performed 14 and 21 days after the last dose administration.
A completion visit will be performed 4 days after the last serological staging (e.g. after cycle 2 on Day 40).
Four dose groups (cohorts) are planned: 0.3 mg/kg followed by doses of 1 mg/kg, 3 mg/kg and 6 mg/kg. Subjects will be enrolled in a strict sequential order.
Individual safety results obtained until Day 5 will be evaluated by the investigator and the sponsor before the next subject of the same dose group will be treated. After completion of all 3 subjects of a dose group, safety results of all subjects obtained until Day 15 will be reviewed by the DSMB and a decision for dose escalation will be made. Interim doses can be administered if the increase is thought to be too high.
Subjects who show definite signs of progressive disease including hypercalcemia, new osteolytic lesions or new soft tissue plasmocytoma will be withdrawn from the study at any time.
In case dose limited toxicity (DLT) was seen in a subject, further dosing of subjects in the same dose group will be discussed with the DSMB, in case of a second DLT in the same dose group dose escalation will be stopped and the study will be continued at the next lower intermediate dose level or the previous tested dose will be regarded as the maximum tolerated dose (MTD). The MTD is defined as the dose level below the dose inducing a DLT in 2 subjects within one dose level.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Wuerzburg, Germany, 97080
- Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female subjects ≥ 18 years of age
- Relapsed or refractory multiple myeloma defined as: Failure of at least 2 previous therapies including an immunomodulatory agent (thalidomide or lenalidomide) and a proteasome inhibitor (unless the subjects were not eligible or refused to receive those treatments), and with progressive disease, defined by an increase of serological or urine myeloma parameters by 25% to the last value
- Presence of serum M-protein ≥ 1 g per 100 mL (≥ 10 g/L) and/or urine M-protein ≥ 200 mg per 24-hour period and/or serum FLCs ≥ 10 mg per 100 mL (≥ 100 mg/L) combined with an abnormal ratio of lambda and kappa chains
- Life expectancy of > 6 months
- Karnofsky performance status ≥ 60%, Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
- Absolute neutrophil count (ANC) ≥ 1.0 (1,000/mm3) and platelets ≥ 30 × 109/L without previous transfusion within the last 2 weeks before first study drug administration
- Creatinine clearance ≥ 30 mL/min (calculated using the Cockcroft-Gault equation)
- Total bilirubin ≤ 2 × upper normal limit (UNL)
- Alanine transaminase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × UNL
- Haemoglobin ≥ 8 g/dL
- If a female of childbearing potential, confirmation of a negative pregnancy test before enrolment and use of double-barrier contraception, oral contraceptive plus barrier contraceptive, or confirmation of having undergone clinically documented total hysterectomy and/or oophorectomy, tubal ligation
- If a male, use of an effective barrier method of contraception during the study and for 3 months after the last dose if sexually active with a female of childbearing potential
- Ability to comply with all study-related procedures, medication use, and evaluations
- Ability to understand and give written informed consent, and comply with the protocol
Exclusion Criteria:
- Primary refractory multiple myeloma
- Previous treatment with cytotoxic chemotherapy or large-field radiotherapy or other myeloma-specific therapy within 28 days prior to the screening visit (radiation to a single site as concurrent therapy is allowed)
- Treatment with a systemic investigational agent within 28 days prior to the screening visit
- Hypercalcemia (> 2.7 mmol/L)
- Extramedullary plasmocytoma not originating from bone or plasma cell leukaemia
- Previous allogenic stem cell transplantation
- Known or suspected hypersensitivity to the excipients contained in the study drug formulation
- Significant uncontrolled cardiovascular disease or cardiac insufficiency (New York Heart Association (NYHA) classes III-IV)
- Prior therapy with other monoclonal antibodies
- Clinical or laboratory evidence of active hepatitis B (positive HBsAg with negative HBsAb) or hepatitis C (positive hepatitis c virus antibody and detectable hepatitis C virus RNA with ALT above the normal range)
- Positive HIV test result (ELISA or Western blot)
- History of ischemic colitis, stroke or myocardial infarction within the last 6 months
- Presence of diarrhoea of grade 2 or higher
- Any active uncontrolled systemic infection
- Any antibiotic therapy due to infections 2 weeks prior to first study drug administration
- Regular dose of corticosteroids during the 2 weeks prior to study entry or anticipated need of corticosteroids exceeding prednisone 20 mg/day or equivalent, or any other immunosuppressive therapy within 2 weeks prior to study entry.
- Major surgery ≤ 4 weeks prior to first study drug administration or ongoing side effects of such surgery
- Systemic diseases (cardiovascular, renal, hepatic, etc) that would prevent study treatment
- Multiple myeloma with central nervous system involvement.
- Second active malignant disease, currently requiring treatment (with the exception of basal cell carcinoma of the skin or curative surgery treated tumours).
- Pregnancy or breastfeeding in women and women of childbearing potential not using an acceptable method of birth control
- others
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Antibody treatment
Intravenous infusion of the anti-GRP78 monoclonal IgM antibody PAT-SM6 group 1: 0.3mg/kg Group 2: 1.0mg/kg Group 3: 3mg/kg Group 4: 6mg/kg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall frequency of adverse events (AEs) (clinical symptoms, laboratory abnormalities, serious adverse events (SAEs) and treatment limiting adverse events)
Time Frame: 14 days
|
14 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Serum concentrations of PAT-SM6
Time Frame: 11 days
|
11 days
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacodynamics
Time Frame: 40 days
|
40 days
|
Efficacy
Time Frame: 40 days
|
40 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Max Top, MD, Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Zentrum für Innere Medizin,
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Neoplasms, Plasma Cell
- Multiple Myeloma
- Physiological Effects of Drugs
- Immunologic Factors
- Antibodies
- Immunoglobulin M
Other Study ID Numbers
- PATCT-SM6-02
- 2012-001893-27 (EUDRACT_NUMBER)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Drug Safety
-
University of DundeeNHS Tayside; NHS FifeCompleted
-
Entera Bio Ltd.Completed
-
West China HospitalCompleted
-
Nanjing Ruijie Pharma Co., Ltd.Recruiting
-
Prolong PharmaceuticalsTerminated
-
SignPath Pharma, Inc.Completed
-
Madrigal Pharmaceuticals, Inc.Completed
-
Mahidol UniversitySiriraj HospitalUnknown
-
Northwestern UniversityActive, not recruiting
-
Madrigal Pharmaceuticals, Inc.Completed
Clinical Trials on Anti-GRP78 monoclonal IgM antibody PAT-SM6
-
Universitaire Ziekenhuizen KU LeuvenUnknownLipid Metabolism, Inborn ErrorsBelgium
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)Active, not recruitingRecurrent Colon Carcinoma | Recurrent Rectal Carcinoma | Rectal Adenocarcinoma | Colon Adenocarcinoma | ERBB2 Gene Amplification | Stage III Colon Cancer AJCC v7 | Stage III Rectal Cancer AJCC v7 | Stage IIIA Colon Cancer AJCC v7 | Stage IIIA Rectal Cancer AJCC v7 | Stage IIIB Colon Cancer AJCC v7 | Stage... and other conditionsUnited States, Puerto Rico
-
Bio-Thera SolutionsActive, not recruitingAdvanced Solid TumorsChina
-
Biotech Pharmaceutical Co., Ltd.Terminated
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | HER2 Positive Breast CarcinomaUnited States
-
Shanghai Henlius BiotechNot yet recruiting
-
Henlix, IncTerminated
-
National Institute of Dental and Craniofacial Research...Terminated
-
Shanghai Henlius BiotechCompleted
-
University of ArizonaNational Cancer Institute (NCI)CompletedLymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous/Nonmalignant ConditionUnited States